Skip to main content

PAPEL DEL EPITRANSCRIPTOMA Y SU IMPLICACION EN LA METASTASIS Y LA RESPUESTA INMUNE EN CANCER

PID2019-111692RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Native RNA nanopore sequencing reveals antibiotic-induced loss of rRNA modifications in the A- and P-sites

  • Delgado-Tejedor, Anna
  • Medina, Rebeca
  • Begik, Oguzhan
  • Cozzuto, Luca
  • López, Judith
  • Blanco, Sandra
  • Ponomarenko, Julia
  • Novoa, Eva Maria
The biological relevance and dynamics of mRNA modifications have been extensively studied; however, whether rRNA modifications are dynamically regulated, and under which conditions, remains unclear. Here, we systematically characterize bacterial rRNA modifications upon exposure to diverse antibiotics using native RNA nanopore sequencing. To identify significant rRNA modification changes, we develop NanoConsensus, a novel pipeline that is robust across RNA modification types, stoichiometries and coverage, with very low false positive rates, outperforming all individual algorithms tested. We then apply NanoConsensus to characterize the rRNA modification landscape upon antibiotic exposure, finding that rRNA modification profiles are altered in the vicinity of A and P-sites of the ribosome, in an antibiotic-specific manner, possibly contributing to antibiotic resistance. Our work demonstrates that rRNA modification profiles can be rapidly altered in response to environmental exposures, and provides a robust workflow to study rRNA modification dynamics in any species, in a scalable and reproducible manner., The work of S.B. work was supported by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (PID2019-111692RB-I00 and PID2022-139598OB-I00), and The Scientific Foundation AECC AECC (LABAE19040BLAN). J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU (FPU19/01190). This work was supported by funds from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (PID2021-128193NB-100 to EMN) and the European Research Council (ERC-StG-2021 No 101042103 to EMN). We acknowledge the support of the MEIC to the EMBL partnership, Centro de Excelencia Severo Ochoa and CERCA Program / Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities

  • Nombela, Paz
  • Miguel-López, Borja
  • Blanco, Sandra
© The Author(s)., RNA modifications have recently emerged as critical posttranscriptional regulators of gene expression programmes. Significant advances have been made in understanding the functional role of RNA modifications in regulating coding and non-coding RNA processing and function, which in turn thoroughly shape distinct gene expression programmes. They affect diverse biological processes, and the correct deposition of many of these modifications is required for normal development. Alterations of their deposition are implicated in several diseases, including cancer. In this Review, we focus on the occurrence of N6-methyladenosine (m6A), 5-methylcytosine (m5C) and pseudouridine (Ψ) in coding and non-coding RNAs and describe their physiopathological role in cancer. We will highlight the latest insights into the mechanisms of how these posttranscriptional modifications influence tumour development, maintenance, and progression. Finally, we will summarize the latest advances on the development of small molecule inhibitors that target specific writers or erasers to rewind the epitranscriptome of a cancer cell and their therapeutic potential., This work was supported by Spanish Ministry of Economy and Innovation (MINECO), Ministry of Science and Innovation and Agencia Estatal de Investigación (AEI) and co-financed by the European Development Regional Fund (FEDER) under grant no. SAF2016–78667-R (AEI/FEDER, UE) and PID2019-111692RB-I00. In addition we acknowledge funding from The Scientific Foundation AECC under grant no. LABAE19040BLAN. BML was supported by Junta de Castilla y León-Fondo Social Europeo (ESF) predoctoral fellowship. AUTHOR’s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epigenetic and Epitranscriptomic Control in Prostate Cancer

  • López, Judith
  • Añazco-Guenkova, Ana M.
  • Monteagudo, Óscar
  • Blanco, Sandra
The initiation of prostate cancer has been long associated with DNA copy-number alter-ations, the loss of specific chromosomal regions and gene fusions, and driver mutations, especially those of the Androgen Receptor. Non-mutational events, particularly DNA and RNA epigenetic dysregulation, are emerging as key players in tumorigenesis. In this review we summarize the molecular changes linked to epigenetic and epitranscriptomic dysregulation in prostate cancer and the role that alterations to DNA and RNA modifications play in the initiation and progression of prostate cancer., This work was funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 grant PID2019-111692RB-I00. In addition, we acknowledge funding from The Scientific Foundation AECC (LABAE19040BLAN), the University of Salamanca and Fundación Memoria de Samuel Solorzano Barruso (FS/36-2020), and Consejería de Educación de la Junta de Castilla y León (CSI264P20) to S.B., A.M.A-G. was supported by USAL-Santander PhD fellowship. J.L. was supported by The Scientific Foundation AECC predoctoral fellowship (PRDSA19002LÓPE) and the Spanish Ministry of Universities predoctoral fellowship (FPU19/01190). The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia, co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

N7-methylguanosine methylation of tRNAs regulates survival to stress in cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • López, Judith
  • Dietmann, Sabine
  • Tomé, Mercedes
  • Jimeno, Sonia
  • Azkargorta, Mikel
  • Elortza, Félix
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Sánchez-Martín, Manuel A.
  • Huertas Sánchez, Pablo
  • Durán, Raúl V.
  • Blanco, Sandra
Tumour progression and therapy tolerance are highly regulated and complex processes largely dependent on the plasticity of cancer cells and their capacity to respond to stress. The higher plasticity of cancer cells highlights the need for identifying targetable molecular pathways that challenge cancer cell survival. Here, we show that N7-guanosine methylation (m7G) of tRNAs, mediated by METTL1, regulates survival to stress conditions in cancer cells. Mechanistically, we find that m7G in tRNAs protects them from stress-induced cleavage and processing into 5' tRNA fragments. Our analyses reveal that the loss of tRNA m7G methylation activates stress response pathways, sensitising cancer cells to stress. Furthermore, we find that the loss of METTL1 reduces tumour growth and increases cytotoxic stress in vivo. Our study uncovers the role of m7G methylation of tRNAs in stress responses and highlights the potential of targeting METTL1 to sensitise cancer cells to chemotherapy., This work was funded by the Spanish Ministry of Science and Innovation MICINN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” (SAF2016-78667-R and PID2019-111692RB-I00), MINECO (RYC-2014-16550), AECC (LABAE19040BLAN), and Consejería de Educación de la Junta de Castilla y León (CSI264P20) to S.B. R.G-V. was supported by MICINN/AEI /10.13039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). A.M.A-G. was supported by USAL-Santander PhD fellowship. J.L. was supported by AECC (PRDSA19002LÓPE) and MIU (FPU19/01190). The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01). R.V.D. work was supported by Agencia Estatal de Investigación/European Regional Development Fund, European Union (PGC2018-096244-B-I00, Ministry of Science and Innovation of Spain, Spanish National Research Council-CSIC (2021AEP005). The authors wish to thank the donors, and the Biobank Hospital Universitario Puerta de Hierro Majadahonda (HUPHM)/Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA) (PT17/0015/0020 in the Spanish National Biobanks Network) for the human specimens used in this study. The authors wish to thank all the core facilities that support the work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizábal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire
  • Fernández, Sonia
  • Paniagua, Alejandro
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Félix
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.
  • De Las Rivas, Javier
  • Guil, Sònia
  • Motorin, Yuri
  • Helm, Mark
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology., This work was funded by the Spanish Ministry of Science and Innovation MICINN/AEI/1013039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” (SAF2016-78667-R and PID2019-111692RB-I00), MINECO (RYC-2014-16550), AECC (LABAE19040BLAN), Proteored-ISCIII, and Consejería de Educación de la Junta de Castilla y León (CSI264P20). R.G-V. was supported by MICINN/AEI/1013039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). A.M.A-G. was supported by the USAL-Santander PhD fellowship. J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU(FPU19/01190). B.M.L. was supported by Junta de Castilla y León ‐ Fondo Social Europeo (ESF). I.M. was supported by the Cris contra el cáncer grant PR_TPD_2020-19. The work of A. Carracedo is supported by the MICINN (PID2019-108787RB-I00 (FEDER/EU); Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded by FEDER funds and ISCIII. The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Global and single-nucleotide resolution detection of 7-methylguanosine in RNA

  • D’Ambrosia, Silvia
  • García-Vílchez, Raquel
  • Kedrac, Darek
  • Vitalie, Patrice
  • Macias-Cámara, Nuria
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Dietmann, Sabine
  • Hurtado, Antonio
  • Blanco, Sandra
RNA modifications, including N-7-methylguanosine (m7G), are pivotal in governing RNA stability and gene expression regulation. The accurate detection of internal m7G modifications is of paramount significance, given recent associations between altered m7G deposition and elevated expression of the methyltransferase METTL1 in various human cancers. The development of robust m7G detection techniques has posed a significant challenge in the field of epitranscriptomics. In this study, we introduce two methodologies for the global and accurate identification of m7G modifications in human RNA. We introduce borohydride reduction sequencing (Bo-Seq), which provides base resolution mapping of m7G modifications. Bo-Seq achieves exceptional performance through the optimization of RNA depurination and scission, involving the strategic use of high concentrations of NaBH4, neutral pH and the addition of 7-methylguanosine monophosphate (m7GMP) during the reducing reaction. Notably, compared to NaBH4-based methods, Bo-Seq enhances the m7G detection performance, and simplifies the detection process, eliminating the necessity for intricate chemical steps and reducing the protocol duration. In addition, we present an antibody-based approach, which enables the assessment of m7G relative levels across RNA molecules and biological samples, however it should be used with caution due to limitations associated with variations in antibody quality between batches. In summary, our novel approaches address the pressing need for reliable and accessible methods to detect RNA m7G methylation in human cells. These advancements hold the potential to catalyse future investigations in the critical field of epitranscriptomics, shedding light on the complex regulatory roles of m7G in gene expression and its implications in cancer biology., This work was funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” [SAF2016-78667-R, PID2019-111692RB-I00, and PID2022-139598OB-I00]. In addition, we acknowledge funding from The Scientific Foundation AECC [LABAE19040BLAN], and the University of Salamanca and Fundación Memoria de Samuel Solorzano Barruso [FS/21-2018, FS/25-2019, FS/36-2020] and Consejería de Educación de la Junta de Castilla y León [CSI264P20] to S.B. S.B. was supported by Ramón y Cajal program from Spanish Ministry of Economy and Innovation [MINECO] [RYC2014-16550]. R.G-V. was supported by a predoctoral fellowship funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund [CLC–2017–01]. S.B., R.G-V., A.H. and D.K. belong to the Spanish National Research Council (CSIC)’s Cancer Hub., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues

  • Añazco-Guenkova, Ana M.
  • Miguel-López, Borja
  • Monteagudo, Óscar
  • García-Vílchez, Raquel
  • Blanco, Sandra
Recent advancements have illuminated the critical role of RNA modifications in post-transcriptional regulation, shaping the landscape of gene expression. This review explores how tRNA modifications emerge as critical players, fine-tuning functionalities that not only maintain the fidelity of protein synthesis but also dictate gene expression and translation profiles. Highlighting their dysregulation as a common denominator in various cancers, we systematically investigate the intersection of both cytosolic and mitochondrial tRNA modifications with cancer biology. These modifications impact key processes such as cell proliferation, tumorigenesis, migration, metastasis, bioenergetics and the modulation of the tumor immune microenvironment. The recurrence of altered tRNA modification patterns across different cancer types underscores their significance in cancer development, proposing them as potential biomarkers and as actionable targets to disrupt tumorigenic processes, offering new avenues for precision medicine in the battle against cancer., The Spanish Ministry of Science and Innovation [MCIN/AEI/ 10.13039/501100011033] and European Regional Development Fund (ERDF) ‘A way of making Europe’ funded this work [PID2019-111692RB-I00 and PID2022-139598OB-I00]. The Spanish Ministry of Science and Innovation [MCIN/AEI/ 10.13039/501100011033] and European Social Fund ‘Investing in your future’ funded a PhD fellowship to R.G-V. [BES-2017-080530]; USAL-Santander funded a PhD fellowship to A.M.A-G.; and Junta de Castilla y León and Fondo Social Europeo (ESF) funded PhD fellowships to B.M-L. and O.M-G., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the role of ribosomal RNA modifications in cancer

  • López, Judith
  • Blanco, Sandra
Recent advances have highlighted the significant roles of post-transcriptional modifications in rRNA in various cancers. Evidence suggests that dysregulation of rRNA modifications acts as a common denominator in cancer development, with alterations in these modifications conferring competitive advantages to cancer cells. Specifically, rRNA modifications modulate protein synthesis and favor the specialized translation of oncogenic programs, thereby contributing to the formation of a protumorigenic proteome in cancer cells. These findings reveal a novel regulatory layer mediated by changes in the deposition of rRNA chemical modifications. Moreover, inhibition of these modifications in vitro and in preclinical studies demonstrates potential therapeutic applications. The recurrence of altered rRNA modification patterns across different types of cancer underscores their importance in cancer progression, proposing them as potential biomarkers and novel therapeutic targets. This review will highlight the latest insights into how post-transcriptional rRNA modifications contribute to cancer progression and summarize the main developments and ongoing challenges in this research area., We acknowledge funding from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (grant numbers PID2019-111692RB-I00 and PID2022-139598OB-I00). J.L. was supported by the Spanish Association Againts Cancer (AECC) (grant number PRDSA19002LÓPE) and the Spanish Ministry of Universities (MIU) (grant number FPU19/01190), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Native RNA nanopore sequencing reveals antibiotic-induced loss of rRNA modifications in the A- and P-sites

  • Delgado-Tejedor, Anna
  • Medina, Rebeca
  • Begik, Oguzhan
  • Cozzuto, Luca
  • López, Judith
  • Blanco, Sandra
  • Ponomarenko, Julia
  • Novoa, Eva Maria
The biological relevance and dynamics of mRNA modifications have been extensively studied; however, whether rRNA modifications are dynamically regulated, and under which conditions, remains unclear. Here, we systematically characterize bacterial rRNA modifications upon exposure to diverse antibiotics using native RNA nanopore sequencing. To identify significant rRNA modification changes, we develop NanoConsensus, a novel pipeline that is robust across RNA modification types, stoichiometries and coverage, with very low false positive rates, outperforming all individual algorithms tested. We then apply NanoConsensus to characterize the rRNA modification landscape upon antibiotic exposure, finding that rRNA modification profiles are altered in the vicinity of A and P-sites of the ribosome, in an antibiotic-specific manner, possibly contributing to antibiotic resistance. Our work demonstrates that rRNA modification profiles can be rapidly altered in response to environmental exposures, and provides a robust workflow to study rRNA modification dynamics in any species, in a scalable and reproducible manner., The work of S.B. work was supported by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (PID2019-111692RB-I00 and PID2022-139598OB-I00), and The Scientific Foundation AECC AECC (LABAE19040BLAN). J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU (FPU19/01190). This work was supported by funds from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (PID2021-128193NB-100 to EMN) and the European Research Council (ERC-StG-2021 No 101042103 to EMN). We acknowledge the support of the MEIC to the EMBL partnership, Centro de Excelencia Severo Ochoa and CERCA Program / Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation

  • Monteagudo, Óscar
  • Nombela, Paz
  • Román, Ángel C.
  • Fernández-Rodero, Vicente
  • Berta, Casar
  • Bhattarai, Devi Prasad
  • Alonso-López, D.
  • Loa-Mesón, Diana
  • Barros-Silva, Diana
  • Henrique, Rui
  • Jerónimo, Carmen
  • Jenster, Guido W.
  • Martens-Uzunova, Elena S.
  • Aguilo, Francesca
  • Blanco, Sandra
Aggressive metastatic cancer remains a major clinical challenge due to the unclear underlying mechanisms and the limited treatment options available. N6-methyladenosine (m6A) is a reversible modification of RNA that is frequently altered in cancer, and inhibitors targeting regulators of this process have been shown to block tumorigenesis. A better understanding of the role of m6A modifications in driving metastatic properties could help reveal potential strategies to prevent and treat metastasis. In this study, we discovered loss of the m6A writer complex component ZC3H13 as a key regulator of metastatic progression. Co-loss of ZC3H13 together with RB1 and BRCA2 occurred in patients with metastatic prostate cancer. Functional in vitro and in vivo assays demonstrated that ZC3H13 loss changes m6A writer complex activity and target specificity, leading to decreased m6A methylation and increased stability of transcripts that promote migration and invasion. Treatment with FDA-approved m6A demethylase inhibitors effectively reduced the metastatic capabilities of ZC3H13-deficient cells. Together, these findings provide insights into how the m6A writer complex selectively methylates mRNAs, highlight the pathological consequences of altered writer complex composition in cancer, and reveal therapeutic avenues for patients with metastatic cancer. , This work was supported by the Spanish Ministry of Science and Innovation (PID2019-111692RB-I00 and PID2022-139598OB-I00), The Scientific Foundation AECC (LABAE19040BLAN), the University of Salamanca and Fundación Memoria de Samuel Solorzano Barruso (FS/36-2020, FS/13-2023). The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01). O.M-G. was supported by Junta de Castilla y León ‐ European Social Fund (ESF) predoctoral fellowship (20229001881660), and by ConexiónCáncer hub JAE Intro ICU fellowship and Programa de apoyo a la movilidad entre grupo fellowship (JAE-ICU-CC-28). V.F-R. was supported by the USAL-Santander PhD fellowship, and The Spanish Ministry of Science, Innovation and Universities (FPU23/01177)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Native RNA nanopore sequencing reveals antibiotic-induced loss of rRNA modifications in the A- and P-sites

  • Delgado-Tejedor, Anna
  • Medina, Rebeca
  • Begik, Oguzhan
  • Cozzuto, Luca
  • López, Judith
  • Blanco, Sandra
  • Ponomarenko, Julia
  • Novoa, Eva Maria
The biological relevance and dynamics of mRNA modifications have been extensively studied; however, whether rRNA modifications are dynamically regulated, and under which conditions, remains unclear. Here, we systematically characterize bacterial rRNA modifications upon exposure to diverse antibiotics using native RNA nanopore sequencing. To identify significant rRNA modification changes, we develop NanoConsensus, a novel pipeline that is robust across RNA modification types, stoichiometries and coverage, with very low false positive rates, outperforming all individual algorithms tested. We then apply NanoConsensus to characterize the rRNA modification landscape upon antibiotic exposure, finding that rRNA modification profiles are altered in the vicinity of A and P-sites of the ribosome, in an antibiotic-specific manner, possibly contributing to antibiotic resistance. Our work demonstrates that rRNA modification profiles can be rapidly altered in response to environmental exposures, and provides a robust workflow to study rRNA modification dynamics in any species, in a scalable and reproducible manner., The work of S.B. work was supported by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (PID2019-111692RB-I00 and PID2022-139598OB-I00), and The Scientific Foundation AECC AECC (LABAE19040BLAN). J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU (FPU19/01190). This work was supported by funds from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (PID2021-128193NB-100 to EMN) and the European Research Council (ERC-StG-2021 No 101042103 to EMN). We acknowledge the support of the MEIC to the EMBL partnership, Centro de Excelencia Severo Ochoa and CERCA Program / Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizabal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Fernández, Sonia
  • Paniagua, Alejandro|||0000-0002-7794-8321
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika|||0000-0001-5164-6803
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Barcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • De Las Rivas, Javier
  • Guil, Sonia|||0000-0002-2257-3331
  • Motorin, Yuri
  • Helm, Mark|||0000-0002-0154-0928
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology.